Member Info for MOG14

from the other place (good post).... technicals looking great...

SYME has broken two resistance lines on high volume in the first hour of trading. Looking to add in the triangular execution zone for a move up. Stochastic oversold on multiple timeframes, MACD turning.

Fintech market is place to be for 2021 and beyond

absolutely HUGE!

GLA

Just thinking back before xmas when we were all expecting 1p

didnt happen, sp retraced some, but since there only positive news and SP gearing up for another assault on 1p

Just doubled my holding in anticipation

GLA

does anyone have any access to L2, hows it looking?

with the price action here over past couple of days, looks to be building stronger from a very low base

once the news is released later this month, these prices will be long gone

time to load up

GLA

Doc, would you be the same Doc i crossed paths with at GKP and the Posh?

when price moves up on no news.....

imagine once the good news breaks later this month

What price then?

good things coming.........

In first 40 minutes!

Volume 3,457,438
Avg. Volume 390,325

bet there are a few fund managers waiting for this to move to main market, so that they are allowed to take up a position here.

look what they are missing now

BTW, how much free float is there for them to bid for ?

hats off to those who sold in London to buy in US last few days

Good move

WOW

small piece on CNBC just a moment ago

To put today's news into context, the vice president of regeneron ($53B M/C) where for 10 years he lead immunology & antibody treatments from pre clinical to post launch, to become a world leader, has joined the board of Tiziana (£300m/$405m M/C) ???? No brainer for me.

Great job Hemo, many congratulations....

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

Unlikely to be listed, more likely a sale of the company, in which case we can expect shares in the acquiring company or cash alternative

IMHO

I agree and im hoping to see 3p before end of this month

GLA

SIMPLY FILTER THEM, THESE GUYS THRIVE ON YOUR REPLIES TO THEIR CAUSTIC POSTS, IN DOING SO YOU SPOIL THIS BOARD

FILETER AND IGNORE

GLA LONG TERM HOLDERS

on CNBC now, expect demand growth for rest of the year

POO going up in price too

Come on PPC, time for people to appreciate how cheap this share price is

GLA

Double the daily average volume in first 90 mnutes

Up 8% to boot

:-)